Prevalence of Delayed Nausea and Vomiting in Patients Being Treated With Oxaliplatin-based Regimens (mFOLFOX6 or FOLFOX7) for Colorectal Cancer
- To assess the prevalence of delayed nausea and vomiting in patients with colorectal
cancer receiving standard anti-emetic medications during the first course of an
oxaliplatin-based chemotherapy regimen (mFOLFOX6 or FOLFOX7).
OUTLINE: This is a multicenter study.
Patients undergo collection of demographic, diagnostic, and treatment data at baseline.
Patients complete the Functional Living Index-Emesis (FLIE) questionnaire at baseline prior
to first chemotherapy infusion and at 5-7 days. Patients also fill out daily patient diaries
about symptoms of nausea and vomiting, and use of medications to prevent these symptoms over
Observational Model: Case-Only, Time Perspective: Prospective
Percentages of Participants by Gender Who Reported Nausea During the First Week of Chemotherapy
Week 1 of FOLFOX chemotherapy
Stewart Barry Fleishman, MD
Beth Israel Medical Center
United States: Federal Government
|Beth Israel Medical Center - Philipps Ambulatory Care Center||New York, New York 10003|